

May 11, 2026

The Honorable Doris Matsui  
2206 Rayburn House Office Building  
Washington, DC 20515

The Honorable Dan Crenshaw  
248 Cannon House Office Building  
Washington, DC 20515

The Honorable Kim Schrier  
1110 Longworth House Office Building  
Washington, DC 20515

The Honorable Ashley Hinson  
2458 Rayburn House Office Building  
Washington, DC 20515

Dear Representatives Matsui, Crenshaw, Schrier and Hinson,

On behalf of Vizient, Inc., I am pleased to offer our endorsement of the *Drug Origin Transparency Act of 2026* ([H.R.8339](#)). This important, bipartisan legislation would enhance transparency in the sourcing and manufacturing of prescription drugs and provide supply chain stakeholders with more timely information to help anticipate and respond to potential drug shortages.

[Vizient, Inc.](#), the nation's largest provider-driven healthcare performance improvement company, serves more than 65% of the nation's acute care providers, including 97% of the nation's academic medical centers, and more than 35% of the non-acute market. The Vizient contract portfolio represents \$140 billion in annual purchasing volume enabling the delivery of cost-effective, high-value care. With its acquisition of Kaufman Hall in 2024, Vizient expanded its advisory services to help providers achieve financial, strategic, clinical and operational excellence. Headquartered in Irving, Texas, Vizient has offices throughout the United States. Learn more at [www.vizientinc.com](http://www.vizientinc.com).

The *Drug Origin Transparency Act of 2026* would establish enhanced reporting and disclosure requirements related to the manufacturing of prescription drugs and active pharmaceutical ingredients (APIs). Under the legislation, manufacturers would regularly submit information to the FDA regarding production facilities and the sourcing of APIs and other materials used in drug manufacturing. Certain origin information would also be reflected in product labeling. These measures would provide stakeholders with greater insight into potential vulnerabilities, giving those in the supply chain an opportunity to find alternative production locations or supplier options before a disruption occurs.

Drug shortages continue to create significant challenges across the healthcare system and Vizient remains committed to working collaboratively with suppliers, manufacturers and providers to help mitigate supply disruptions. We are pleased to support efforts to enhance reporting and disclosures related to drug manufacturing and sourcing.

Thank you for your ongoing leadership on this issue. Please do not hesitate to contact me at [shoshana.krilow@vizientinc.com](mailto:shoshana.krilow@vizientinc.com) or 202-354-2607 if you have any questions about Vizient or if there is any way we can be of assistance in advancing your important legislation.

Sincerely,



Shoshana Krilow  
Senior Vice President, Public Policy & Government Relations